Pathogenetically based therapy for cyclic mastalgia
- Authors: Tazina T.V.1
-
Affiliations:
- Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of the Russian Federation
- Issue: No 9 (2020)
- Pages: 187-190
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/329642
- DOI: https://doi.org/10.18565/aig.2020.9.187-190
- ID: 329642
Cite item
Open Access
Access granted
Abstract
Objective. To present their own experience with Indinol Forto in the treatment of breast pain in cyclic mastalgia in patients with benign mammary dysplasia. Materials and methods. Thirty-two women with confirmed benign mammary dysplasia who had taken Indinol Forto 200 mg twice daily before meal for 6 months were examined and treated in during the period 2017-2018. The patients’ mean age was 40.9+11.2 years. Results. Reduced breast pain in cyclic mastalgia of varying intensity was noted in all the patients. Decreases in the sizes and number of cysts were conf irmed by ultrasound. The drug was recorded to have good tolerance; no moderate or severe adverse events were noted. Conclusion. The authors’ experience has conf irmed that Indinol Forto can be used as one of the first-line agents in the treatment of cyclic mastalgia, including in patients with benign mammary dysplasia.
Full Text
About the authors
Tatyana V. Tazina
Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of the Russian Federation
Email: tazina@inbox.ru
candidate of medical sciences, assistant professor of the Department of Surgery, Obstetrics and Gynecology, Faculty of Additional Supplementary Professional Education
References
- Андреева Е.Н., Рожкова Н.И., Соколова Д.А. Доброкачественные дисплазии молочных желез: патогенетический вектор лечения. Обзор исследований, клинические рекомендации: информационный бюллетень. М.: Редакция журнала StatusPraesens; 2016. 24c.
- Коган И.Ю., Мясникова М.О. Диагностика и лечение мастопатии. СПб.: Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова 2010. 32с.
- Onstad M., Stuckey A. Benign breast disorders. Obstet. Gynecol. Clin. North Am. 2013; 40(3): 459-73.
- Письмо Министерства здравоохранения РФ от 7 ноября 2018 г. № 15-4/10/2-7235 «О направлении клинических рекомендаций (протокола лечения) "Доброкачественная дисплазия молочной железы"».
- Iddon J., Dixon M. Mastalgia. BMJ. 2013; 347: f3288. https://dx.doi. org/10.1136/bmj.f3288.
- Olawaiye A., Withiam-Leitch M., Danakas G., Kahn K. Mastalgia: a review of management. J. Reprod. Med. 2005; 50(12): 933-9.
- Радзинский В.Е., ред. Молочные железы и гинекологические болезни, М.; 2010. 304с.
- Silvera S., Rohan T. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Res. Treat. 2008; 110(3): 397-409. https://dx.doi.org/10.1007/s10549-007-9740-3.
- Коган И.Ю. Мастопатия: фиброзно-кистозная болезнь. Учебнометодическое пособие. СПб.: Изд-во Н-Л; 2008. 40с.
- Plu-Bureau G., Le M.G., Sitruk-Ware R., Thalabard J.C. Cyclical mastalgia and breast cancer risk: results of a French cohort study. Cancer Epidemiol. Biomarkers Prev. 2006; 15(6): 1229-31. https://dx.doi.org/10.1158/1055-9965. EPI-05-0745.
- Telang N.T., Suto A., Wong G.Y., Osborne M.P., Bradlow H.L. Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J. Natl. Cancer Inst. 1992; 84(8): 634-8. https://dx.doi.org/10.1093/jnci/84.8.634.
- Трошина Е.А., Румянцев П.О., Алташина М.В., Плохая А.А. Влияние избыточной массы тела и ожирения на факторы риска развития рака молочной железы у женщин в постменопаузе. Ожирение и метаболизм. 2012; 9(3): 3-10.
- Ковалева Ю.В. Гормоны жировой ткани и их роль в формировании гормонального статуса и патогенезе метаболических нарушений у женщин. Артериальная гипертензия. 2015; 21(4): 356-70.
- Телетаева Г.М. Цитокины и противоопухолевый иммунитет. Практическая онкология. 2007; 8(4): 211-8.
- Берштейн Л.М. Гормональный канцерогенез. Санкт-Петербург: Наука; 2000. 199с.
- Ahmad A., Sakr W.A., Rahman K.M. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr. Drug Targets. 2010; 11(6): 652-66. https://dx.doi.org/10.2174/138945010791170923.
Supplementary files
